Literature DB >> 29155240

Matrix Metalloproteinases: A challenging paradigm of cancer management.

Ali Alaseem1, Khalid Alhazzani2, Priya Dondapati3, Saad Alobid2, Anupam Bishayee4, Appu Rathinavelu5.   

Abstract

Matrix metalloproteinases (MMPs) are members of zinc-dependent endopeptidases implicated in a variety of physiological and pathological processes. Over the decades, MMPs have been studied for their role in cancer progression, migration, and metastasis. As a result, accumulated evidence of MMPs incriminating role has made them an attractive therapeutic target. Early generations of broad-spectrum MMP inhibitors exhibited potent inhibitory activities, which subsequently led to clinical trials. Unexpectedly, these trials failed to meet the desired goals, mainly due to the lack of efficacy, poor oral bioavailability, and toxicity. In this review, we discuss the regulatory role of MMPs in cancer progression, current strategies in targeting MMPs for cancer treatment including prodrug design and tumor imaging, and therapeutic value of MMPs as biomarkers in breast, lung, and prostate cancers.
Copyright © 2017 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Biomarker; Cancer; Matrix metalloproteinase; Matrix metalloproteinase inhibitors

Mesh:

Substances:

Year:  2017        PMID: 29155240     DOI: 10.1016/j.semcancer.2017.11.008

Source DB:  PubMed          Journal:  Semin Cancer Biol        ISSN: 1044-579X            Impact factor:   15.707


  57 in total

1.  Farnesoid X receptor represses matrix metalloproteinase 7 expression, revealing this regulatory axis as a promising therapeutic target in colon cancer.

Authors:  Zhongsheng Peng; Jiayan Chen; Cinthia B Drachenberg; Jean-Pierre Raufman; Guofeng Xie
Journal:  J Biol Chem       Date:  2019-04-09       Impact factor: 5.157

2.  C/EBPβ regulates the M2 transcriptome in β-adrenergic-stimulated macrophages.

Authors:  Donald M Lamkin; Shreyesi Srivastava; Karen P Bradshaw; Jenna E Betz; Kevin B Muy; Anna M Wiese; Shelby K Yee; Rebecca M Waggoner; Jesusa M G Arevalo; Alexander J Yoon; Kym F Faull; Erica K Sloan; Steve W Cole
Journal:  Brain Behav Immun       Date:  2019-05-24       Impact factor: 7.217

3.  Macromolecule-Network Electrostatics Controlling Delivery of the Biotherapeutic Cell Modulator TIMP-2.

Authors:  Yuji Yamada; Ananda Chowdhury; Joel P Schneider; William G Stetler-Stevenson
Journal:  Biomacromolecules       Date:  2018-03-19       Impact factor: 6.988

Review 4.  Role of NKG2D and its ligands in cancer immunotherapy.

Authors:  Huifang Liu; Sijia Wang; Jing Xin; Jing Wang; Cuiping Yao; Zhenxi Zhang
Journal:  Am J Cancer Res       Date:  2019-10-01       Impact factor: 6.166

5.  Co-expression of TLR-9 and MMP-13 is associated with the degree of tumour differentiation in prostate cancer.

Authors:  Elham Kalantari; Maryam Abolhasani; Raheleh Roudi; Mohammad M Farajollahi; Seif Farhad; Zahra Madjd; Shaghayegh Askarian-Amiri; Monireh Mohsenzadegan
Journal:  Int J Exp Pathol       Date:  2019-05-14       Impact factor: 1.925

6.  LncRNA Pnky Positively Regulates Neural Stem Cell Migration by Modulating mRNA Splicing and Export of Target Genes.

Authors:  Jiannan Du; Yuan Li; Yuting Su; Wenqian Zhi; Jiale Zhang; Cheng Zhang; Juan Wang; Wensheng Deng; Shasha Zhao
Journal:  Cell Mol Neurobiol       Date:  2022-06-24       Impact factor: 5.046

Review 7.  MMPs and ADAMs/ADAMTS inhibition therapy of abdominal aortic aneurysm.

Authors:  Yongqi Li; Weicheng Wang; Lei Li; Raouf A Khalil
Journal:  Life Sci       Date:  2020-04-10       Impact factor: 5.037

8.  MDM2 Derived from Dedifferentiated Liposarcoma Extracellular Vesicles Induces MMP2 Production from Preadipocytes.

Authors:  Lucia Casadei; Federica Calore; Danielle A Braggio; Abeba Zewdu; Ameya A Deshmukh; Paolo Fadda; Gonzalo Lopez; Martin Wabitsch; Chi Song; Jennifer L Leight; Valerie P Grignol; Dina Lev; Carlo M Croce; Raphael E Pollock
Journal:  Cancer Res       Date:  2019-08-06       Impact factor: 12.701

Review 9.  The Interplay of the Extracellular Matrix and Stromal Cells as a Drug Target in Stroma-Rich Cancers.

Authors:  Nina Kozlova; Joseph E Grossman; Marcin P Iwanicki; Taru Muranen
Journal:  Trends Pharmacol Sci       Date:  2020-01-31       Impact factor: 14.819

10.  Downregulation of miR‑29b‑3p promotes α‑tubulin deacetylation by targeting the interaction of matrix metalloproteinase‑9 with integrin β1 in nasal polyps.

Authors:  Zhuohui Liu; Haoyu Liu; Deshun Yu; Jingyu Gao; Biao Ruan; Ruiqing Long
Journal:  Int J Mol Med       Date:  2021-05-13       Impact factor: 4.101

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.